BillionToOne, Inc. (BLLN) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BillionToOne (BLLN) is a hot IPO momentum candidate, with an 11% post-IPO rally, strong cash position, improving earnings metrics, and robust technical breakout above moving averages and upper Bollinger Band, although near-term overbought conditions suggest cautious positioning.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high liquidity ⢠High gross margins ⢠Weak profitability BLLN combines very high liquidity, strong gross margins and positive FCF with weak operating profitability, negative retained earnings and heavy financing reliance, while valuation multiples are extremely stretched.
Price Behavior
Key Price Behavior Insights: ⢠Below short-term avg ⢠$70 support tested ⢠Midâ$80sâ$90s resistance Support Level: $70 Resistance Level: $85â$95 Price action is bearish over the last month, trading below its last-month average with a tested near-term support around $70 but likely to stall under resistance in the midâ$80sâmidâ$90s after a >20% midâFeb to earlyâMar selloff.
Sentiment & News
Key News Insights: ⢠Raised guidance ⢠113% Q4 growth ⢠Profitability achieved BillionToOne raised 2026 revenue guidance to $430â$445M after reporting 113% YoY Q4 sales growth driven by prenatal testing, beating expectations, achieving profitability, and prompting a mixed analyst view and volatile intraday trading.
AI Summary
BLLN has transitioned from a promiseâstage R&D story to an early profitable commercial operator with strong unit economics and a ~$496M cash buffer, so investors must now trade nearâterm execution (revenue cadence, ASP/mix stability, and EBITDA margin sustainability) rather than longâdated tech optionality. The single highestâimpact catalyst is payer outcomes (United/MolDx and Medicare/state coverage) â monitor their timing/language and any quarterâtoâquarter ASP or mix shifts closely, because adverse results would rapidly erode the richly priced valuation.
Description
BillionToOne, Inc. is a precision diagnostics company that quantifies DNA at single-molecule resolution to support molecular diagnostic applications. Its platform underlies a non-invasive prenatal screen that evaluates fetal chromosomal and genetic risks from maternal blood and a suite of liquid biopsy tests for tumor mutation profiling and methylation-based monitoring of cancer burden. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | BLLN | BillionToOne, Inc. | BillionToOne (BLLN) is a hot IPO momentum candidate, with an 11% post-IPO rally, strong cash position, improving earnings metrics, and robust technical breakout above moving averages and upper Bollinger Band, although near-term overbought conditions suggest cautious positioning. | Closed | -11.5% |